BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2426299)

  • 1. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.
    Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K
    J Clin Endocrinol Metab; 1986 Sep; 63(3):605-12. PubMed ID: 2426299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.
    Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
    Eur J Clin Pharmacol; 1989; 36(2):133-7. PubMed ID: 2470592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional distribution and in vivo release of tachykinin-like immunoreactivities in rat brain: evidence for regional differences in relative proportions of tachykinins.
    Lindefors N; Brodin E; Theodorsson-Norheim E; Ungerstedt U
    Regul Pept; 1985 Mar; 10(2-3):217-30. PubMed ID: 2581287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreactive tachykinins in 24-h collections of urine from patients with carcinoid tumours: characterization and correlation with plasma concentrations.
    Bergstrom M; Theodorsson E; Norheim I; Oberg K
    Scand J Clin Lab Invest; 1995 Dec; 55(8):679-89. PubMed ID: 8903838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog.
    Vinik AI; Gonin J; England BG; Jackson T; McLeod MK; Cho K
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1702-9. PubMed ID: 1693375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival.
    Norheim I; Oberg K; Theodorsson-Norheim E; Lindgren PG; Lundqvist G; Magnusson A; Wide L; Wilander E
    Ann Surg; 1987 Aug; 206(2):115-25. PubMed ID: 2440390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors.
    Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K; Lundqvist G; Rosell S
    Regul Pept; 1984 Nov; 9(4):245-57. PubMed ID: 6084259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients.
    Theodorsson-Norheim E; Norheim I; Oberg K; Brodin E; Lundberg JM; Tatemoto K; Lindgren PG
    Biochem Biophys Res Commun; 1985 Aug; 131(1):77-83. PubMed ID: 2412557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities.
    Lundin L; Norheim I; Landelius J; Oberg K; Theodorsson-Norheim E
    Circulation; 1988 Feb; 77(2):264-9. PubMed ID: 2448062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements.
    Oberg K; Theodorsson-Norheim E; Norheim I
    Scand J Gastroenterol; 1987 Nov; 22(9):1041-8. PubMed ID: 2447632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tachykinins in endocrine tumors and the carcinoid syndrome.
    Cunningham JL; Janson ET; Agarwal S; Grimelius L; Stridsberg M
    Eur J Endocrinol; 2008 Sep; 159(3):275-82. PubMed ID: 18524798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flushing in the carcinoid syndrome and plasma kallikrein.
    Lucas KJ; Feldman JM
    Cancer; 1986 Nov; 58(10):2290-3. PubMed ID: 2428458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease.
    Makridis C; Theodorsson E; Akerström G; Oberg K; Knutson L
    J Gastroenterol Hepatol; 1999 May; 14(5):500-7. PubMed ID: 10355517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing features of idiopathic flushing and carcinoid syndrome.
    Aldrich LB; Moattari AR; Vinik AI
    Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors.
    Richter G; Stöckmann F; Conlon JM; Creutzfeldt W
    Gastroenterology; 1986 Sep; 91(3):612-8. PubMed ID: 2426155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush.
    Conlon JM; Deacon CF; Richter G; Stöckmann F; Creutzfeldt W
    Scand J Gastroenterol; 1987 Jan; 22(1):97-105. PubMed ID: 2882598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical diagnosis of neuroendocrine GEP tumor.
    Oberg K
    Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.
    Ahlman H; Dahlström A; Grönstad K; Tisell LE; Oberg K; Zinner MJ; Jaffe BM
    Ann Surg; 1985 Jan; 201(1):81-6. PubMed ID: 2578277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulation of a fragment of haemoglobin alpha-chain during a pentagastrin-induced flush in patients with metastatic carcinoid tumours.
    Balks HJ; Thim L; Conlon JM
    Clin Endocrinol (Oxf); 1988 Mar; 28(3):261-9. PubMed ID: 3168309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.